Salarius Pharmaceuticals (NASDAQ:SLRX) Releases Earnings Results

Salarius Pharmaceuticals (NASDAQ:SLRX) announced its earnings results on Friday. The company reported ($0.66) earnings per share for the quarter, Zacks reports.

Salarius Pharmaceuticals Stock Up 6.4 %

Shares of NASDAQ SLRX opened at $0.95 on Friday. Salarius Pharmaceuticals has a twelve month low of $0.83 and a twelve month high of $7.20. The stock’s 50 day moving average price is $1.72 and its 200-day moving average price is $1.61. The company has a market capitalization of $1.65 million, a PE ratio of -0.12 and a beta of 0.59.

Salarius Pharmaceuticals Company Profile

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.